A Single-And Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-890 Tablets in Healthy Chinese Subjects
NCT ID: NCT06506591
Last Updated: 2025-03-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
106 participants
INTERVENTIONAL
2023-10-26
2024-08-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase I Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-910 in Healthy Participants
NCT06897813
Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of YD0293 in Healthy Subjects
NCT07098091
Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of MT921 in Healthy Subjects
NCT03905291
A Phase 1 Study of TT-00920 in Healthy Subjects
NCT05355129
Single Ascending Dose Study of 9MW3011 in Chinese Healthy Subject
NCT06389942
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
OTHER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
WD-890 1mg
Take a fixed dose of WD-890 tablets orally
WD-890
Administered P.O.
WD-890 3mg
Take a fixed dose of WD-890 tablets orally
WD-890
Administered P.O.
WD-890 6mg
Take a fixed dose of WD-890 tablets orally
WD-890
Administered P.O.
WD-890 9mg
Take a fixed dose of WD-890 tablets orally
WD-890
Administered P.O.
WD-890 Tablets Placebo
Take a fixed dose of WD-890 tablets Placebo orally
WD-890 Tablets Placebo
Administered P.O.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
WD-890
Administered P.O.
WD-890 Tablets Placebo
Administered P.O.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 Years to 50 Years (Adult).
* Body mass index (BMI) of 19 to 26 kg/m2, inclusive, and total body weight ：male \>=50 kg; female \>= 45.0 kg.
Exclusion Criteria
* Inability to swallow solid tablets.
* Inability to be venipunctured and tolerate venous access.
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zhejiang Wenda Pharma Technology LTD.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WENDA890ZQ
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.